A phase I-II study of epirubicin, 5-fluorouracil, and leucovorin in advanced adenocarcinoma of the stomach
| Autor: | Werner Scheithauer, Gabriela Kornek, Harald Rosen, Werner Kwasny, Franz Schulz, Christian Sebesta, Dieter Depisch |
|---|---|
| Rok vydání: | 1993 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Nausea medicine.medical_treatment Leucovorin Adenocarcinoma Gastroenterology Stomach Neoplasms Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Aged Epirubicin Chemotherapy Dose-Response Relationship Drug business.industry Stomach Combination chemotherapy Middle Aged Surgery Regimen medicine.anatomical_structure Oncology Fluorouracil Vomiting Female medicine.symptom business medicine.drug |
| Zdroj: | Cancer. 71(7) |
| ISSN: | 0008-543X |
| Popis: | Background. To determine the maximum tolerated dose of epirubicin for use in combination with 5-fluorouracil (5-FU) and low-dose leucovorin (LV), a Phase I–II trial was conducted in 37 patients with advanced gastric carcinoma. Methods. The doses of 5-FU (425 mg/m2) and LV (20 mg/m2), both given intravenously on days 1–5, were held constant while the dose of epirubicin was escalated in cohorts of patients (beginning dose, 50 mg/m2 on day 1). Cycles were repeated every 4 weeks. Results. Significant gastrointestinal symptoms and myelosuppression were observed infrequently at the initial dose level. At a dose of 60 mg/m2 of epirubicin on day 1, however, five of eight patients had significant mucosal toxic effects during the first cycle of therapy. In addition, two patients treated at this dose level had Grade 4 granulocytopenia with insufficient recovery to permit a second course by day 28, and one patient each had severe diarrhea and nausea and vomiting. Among 37 patients with assessable disease, there were 3 complete and 11 partial responses (response rate, 38%). Conclusions. LV modulation of 5-FU can be incorporated safely into combination chemotherapy with epirubicin and provides a relatively active regimen for treatment of disseminated gastric cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text